Table 3.
Clinical Studies for evaluation of Lopinavir/Ritonavir and Interferons (https://clinicaltrials.gov/ct2/results).
| Clinical Trial Number | Study Description | Phase | Dose | Location |
|---|---|---|---|---|
| NCT04276688 | Utilization of Lopinavir/Ritonavir, Ribavirin and IFN-beta Combination against nCoV Treatment | 2 |
Lopinavir/ritonavir: 400 mg and 100 mg respectively administered twice daily for 14 days Ribavirin: 400 mg twice administered daily for 14 days Interferon Beta-1B: 0.25 mg subcutaneous injection administered alternatively for 3 days |
Hong Kong |
| NCT04251871 | Treatment and Prevention of COVID-19 infection with Traditional Chinese Medicines | Not Applicable |
alfa interferon: aerosol inhalation lopinavir and ritonavir:400 mg of lopinavir and 100 mg of ritonavir bid for 2 weeks. |
China |
| NCT04315948 | Clinical Trial of various Treatments for Hospitalized adult patients against COVID-19 | 3 |
Lopinavir/ritonavir: 200 mg Lopinavir and 50 mg Ritonavir IFN-ß-1a: one dose 44 μg/0.5 ml |
France |